Literature DB >> 15721416

Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience.

T Agorastos1, K Dinas, B Lloveras, S de Sanjose, J R Kornegay, H Bonti, F X Bosch, T Constantinidis, J Bontis.   

Abstract

OBJECTIVE: To compare the performance of human papillomavirus (HPV) DNA detection against routine Papanicolaou smear for the detection of low- and high-grade cervical intraepithelial neoplasia in a low-risk population.
MATERIALS AND METHODS: A cross-sectional study was performed involving 1296 women attending six outpatient clinics in Northern Greece (Thessaloniki, Thermi, Mihaniona, Corfu, Veria, and Serres). Women underwent a gynecological examination, including collection of exfoliated cervical cells for Papanicolaou cytology and HPV DNA detection. Cytology was processed according the conventional routine manner, and HPV DNA was determined using the polymerase chain reaction technique. In positive cases of either method, a complete colposcopic evaluation was performed with directed biopsies. Tests (HPV DNA, cytology, and colposcopy) performance characteristics were determined using the histopathologic diagnosis as the reference standard.
RESULTS: HPV DNA testing showed a significantly better sensitivity than the Papanicolaou smear in detecting cervical intraepithelial neoplasia (75% versus 50% for high-grade lesions and 81.2% versus 50% for lesions of any grade, respectively). Specificity, and positive and negative predictive values did not significantly differ. Even after dividing women in younger or older than 30 years, the sensitivity of the HPV DNA test was greater than cytology (100% and 70% versus 50% for cytology in both groups, respectively), with a 6.3% loss in specificity when performed in women younger than 30 years.
CONCLUSION: HPV testing could be useful in screening women at low risk for cervical cancer, either as an adjunct tool to augment existing cytology programs or as a unique test of its own.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721416     DOI: 10.1016/j.ygyno.2004.11.042

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China.

Authors:  Suzanne E Belinson; Na Wulan; Ruizhen Li; Wei Zhang; Xuan Rong; Yasha Zhu; Ruifang Wu; Jerome L Belinson
Journal:  Int J Gynecol Cancer       Date:  2010-08       Impact factor: 3.437

2.  Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.

Authors:  Francesca Carozzi; Simonetta Bisanzi; Cristina Sani; Marco Zappa; Silvia Cecchini; Stefano Ciatto; Massimo Confortini
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

3.  Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.

Authors:  Theodoros Agorastos; Kimon Chatzistamatiou; Taxiarchis Katsamagkas; George Koliopoulos; Alexandros Daponte; Theocharis Constantinidis; Theodoros C Constantinidis
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 4.  Clinical Practice Guidelines on the Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention in Saudi Arabia.

Authors:  Hazem Mahmoud Al-Mandeel; Emad Sagr; Khalid Sait; Hassan Mohamed Latifah; Abdulaziz Al-Obaid; Ismail A Al-Badawi; Abdulmohsen O Alkushi; Hany Salem; Nada S Massoudi; Holger Schunemann; Reem A Mustafa; Romina Brignardello-Petersen
Journal:  Ann Saudi Med       Date:  2016 Sep-Oct       Impact factor: 1.526

5.  Diagnostic Test Accuracy Review of Cytology for Squamous Intraepithelial Lesion and Squamous Cell Carcinoma of Uterine Cervix.

Authors:  Jung-Soo Pyo; Guhyun Kang; Hye Kyoung Yoon; Hyun Jung Kim
Journal:  J Korean Med Sci       Date:  2019-01-02       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.